|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's range||0.000 - 0.000|
|PE ratio (TTM)||20.79|
|Forward Dividend & Yield||1.03 (3.27%)|
|1y target est||N/A|
Roche Holding AG’s top-selling drug Rituxan saw sales slide in Europe last quarter, hurt by competition from cheaper copycat medicines called biosimilars -- a harbinger of things to come for the aging ...
At Biogen's (BIIB) Q3 call, investor focus will remain on Tecfidera's scrip trends, pipeline progress and acquisition plans. All eyes will also be on Spinraza's performance in the same quarter.
ImmunoGen (IMGN) plans to move its leukemia candidate, IMGN632, into phase I study before the year ends. Also, the FDA has completed the safety review of its IND application for IMGN632.
Inovio Pharmaceuticals (INO) will evaluate a combination of checkpoint inhibitor and T cell activator as a potential treatment for advanced bladder cancer in a new early stage study.
Roche Holdings’ oncology business accounts for over 50% of the company valuation, according to our estimates. The company’s blockbuster oncology drugs are Avastin, Herceptin and MabThera/Rituxan. These three drugs alone accounted for roughly 40% of the company’s overall revenues in 2016
Landmark Roche patents that helped launch the modern biotechnology era end next year, extinguishing a source of billions of dollars in income for the Swiss drugmaker and piling pressure on its new medicines to succeed. Roche's so-called "Cabilly patents" protect a pivotal step in manufacturing therapeutic antibodies, but end on Dec. 18, 2018. For decades, these patents allowed Roche to extract cash from dozens of drugmakers.
AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Allergan (AGN) announced that the FDA has accepted the application for the label expansion of Avycaz to include a new indication and study data.
Roche Holdings AG (RHHBY) announced that the FDA has accepted the company's sBLA and granted Priority Review for breast cancer drug regimen Perjeta
Prothena Corporation plc (PRTA) announced disappointing results from a phase Ib study of pipeline candidate, PRX003 in psoriasis patients.
A drug Roche had hoped would prevent loss of vision and become a big seller failed a late-stage trial, leading some analysts to say on Friday it now had no future. Lampalizumab, which was being trialled to treat a form of age-related macular degeneration, did not reduce changes in lesion area compared to a placebo after a year, Roche said.
Giving Merck & Co's immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial. U.S. regulators approved the drug cocktail in May but the limited clinical trial data to date means that questions still remain as to whether it will retain its effectiveness over time.
Roche raised its 2007 outlook after first-half profit beat market expectations just as the Swiss group's ageing portfolio of blockbuster medicines faces increasing competition.
A run of disappointing drug trials at Roche has left analysts suggesting the view from its new 41-storey office building in Basel has become more clouded, with little chance of management now upgrading its growth forecast next week, when it reports first-half earnings. "Their impact in the second half might limit Roche's chances of upgrading 2017 guidance," he said.
Swiss drugmaker Roche's bid to take a chunk of the $11 billion haemophilia drug market dominated by Shire took another blow with the Irish company winning a preliminary injunction over its Swiss rival's medication. Shire said its injunction in a court in Germany, where Roche presented data on its drug emicizumab on Monday, sought to remedy Roche's "incomplete and misleading" statements about the role of Shire's drug FEIBA in adverse events in Roche trials.
Roche's bid to muscle in on Shire's share of the $11 billion haemophilia drug market took a new, contentious turn this weekend when the British drugmaker won a court injunction against how the Swiss drugmaker talks about its new medicine. Shire's injunction on Sunday in a Hamburg, Germany, court alleges incomplete and misleading statements by Roche about its investigational emicizumab.
Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine. Haemophilia patients' blood does not clot properly, requiring life-saving infusions of clotting factors.
Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients who had developed resistance to standard treatment, compared with those who instead got bypassing agents, the Swiss company said on Monday. In the late-stage study, 62.9 percent of patients receiving emicizumab experienced zero treated bleeds compared to 5.6 percent of those receiving so-called bypassing agents, Roche said. Development of resistance, or inhibitors, in many of those being treated can interfere with efforts to control their bleeding, so Roche is hoping its drug, also known as ACE910, will offer a new avenue of treatment.
A Roche breast cancer drug at the centre of a prolonged pricing row in Britain will now be paid for routinely, following a discount deal between the company and the National Health Service (NHS). Kadcyla, which can prolong the lives of some women with advanced disease, has been a battle-ground for campaigners wanting better access to modern cancer drugs, with 115,000 people signing a petition demanding its availability. The National Institute for Health and Care Excellence (NICE (Other OTC: NCSYF - news) ) said on Thursday it could now recommend funding for Kadcyla, following the new commercial access arrangement with Roche.
Roche is hoping to win a slice of the $11 billion-a-year haemophilia drug market with the drug, also known as ACE910 and designed to compete with more traditional treatments from Novo Nordisk and Shire (Xetra: S7E.DE - news) . Roche's drug is being closely watched because it could change the way the disease is treated. Haemophilia patients, whose blood does not clot properly, need life-saving infusions of clotting factors, but development of inhibitors in many of those being treated can interfere with efforts to control their bleeding.
Roche Holding AG's emicizumab drug for treating haemophilia A met its primary endpoint in a phase III study, the Swiss drugmaker said on Thursday. "The study showed a statistically significant reduction ...